Skip to main content
Signal8
Launch Terminal

Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc.

NASDAQ:MLYSHealthcare
-14.41%$18.18
AH$18.29+0.61%vs close
Mkt Cap$1.61B
Float63.89M
O/S88.41M
Vol
$ Vol
RVOL
Inst Own-
SI11.6%
Earnings
Dilution
Mineralys Therapeutics, Inc. logoNASDAQ:MLYS$18.18-14.41%
FormDescription
8-K
1.01,1.02
3
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
8-K
5.02,9.01
144
Notice of Proposed Sale of Securities
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
4
Statement of Changes in Beneficial Ownership

1-25 of 406

…

Recent SEC filings with analysis

    Mineralys Therapeutics, Inc. (MLYS) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8